EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Predicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease

Thomas Bais iD, Martine G E Knol iD, Laixi Xue iD, Paul Geertsema iD, Priya Vart, Franz Reichel iD, Sita Arjune iD, Roman-Ulrich Müller iD, Shosha E I Dekker iD, Mahdi Salih iD, Esther Meijer iD, Ron T Gansevoort iD und 1 weitere

Clinical Journal of the American Society of Nephrology · 2025-05 · 20 (5) · 608-618

DOI: 10.2215/cjn.0000000680 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 11.03.2025. Verfasst von Thomas Bais und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University Medical Center, University of Groningen, Groningen, The Netherlands. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Risk prognostication in autosomal dominant polycystic kidney disease can be improved by combining clinical, genetic, and volumetric data. Various biomarkers have been explored in autosomal dominant polycystic kidney disease, but it is unclear which biomarkers are most suitable to integrate into risk stratification tools. Urinary albumin/creatinine, monocyte chemotactic protein-1/creatinine, and serum copeptin are independently associated with kidney outcomes, even in early disease and MIC 1C.

Background

Risk stratification tools for autosomal dominant polycystic kidney disease (ADPKD) predict kidney outcomes on a group level but lack precision in patients.

Methods

We assessed the value of adding 13 prognostic biomarkers to established risk factors (sex, age, eGFR, systolic BP, Mayo Imaging Classification [MIC], and mutation type) for predicting disease progression. We included 596 patients from the Developing Intervention Strategies to Halt Progression of ADPKD cohort with ≥2 eGFR measurements and ≥1-year follow-up.

Results

During a mean±SD follow-up of 5.0±2.3 years, the mean±SD eGFR slope was −3.46±2.5 ml/min per 1.73 m 2 per year. Rapid disease progression (eGFR loss ≥3 ml/min per 1.73 m 2 per year) occurred in 303 patients (50.8%), and 279 patients (46.8%) reached the combined end point of kidney failure or 30% eGFR decline. Urinary albumin/creatinine, urinary monocyte chemotactic protein-1/creatinine, and serum copeptin consistently and independently predicted eGFR slope (all P < 0.001), rapid disease progression (area under the curve increasing from 0.79 [95% confidence interval (CI), 0.76 to 0.85] for a baseline model to 0.83 [95% CI, 0.81 to 0.88] when monocyte chemotactic protein-1/creatinine and copeptin were included, P = 0.006), and reaching the combined kidney end point (C-index improving from 0.806 [95% CI, 0.78 to 0.84] for a baseline model to 0.82 [95% CI, 0.79 to 0.85] for a model also containing albumin/creatinine and copeptin, P < 0.001). These results were confirmed in an independent external validation cohort ( N =144) and were robust in early disease stages and in patients with moderately increased kidney volumes (MIC 1C).

Conclusions

Our findings suggest that incorporating these biomarkers into ADPKD risk stratification tools will improve risk prediction, even in subgroups where prognostication is most challenging and relevant.

Schlagwörter

Stichwörter der Autor:innen

ADPKDCKDMCP-1 (monocyte chemoattractant protein 1)albuminuriabiomarkerspolycystic kidney disease

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, University Medical Center, University of Groningen, Groningen, The Netherlands.
  • Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
  • Department II of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Thomas Bais, Martine G E Knol, Laixi Xue, Paul Geertsema, Franz Reichel, Sita Arjune, Roman-Ulrich Müller, Shosha E I Dekker, Mahdi Salih, Esther Meijer, Ron T Gansevoort

Zitieren

APA

Bais, T., Knol, M. G. E., Xue, L., Geertsema, P., Vart, P., Reichel, F., Arjune, S., Müller, R. U., Dekker, S. E. I., Salih, M., Meijer, E., Gansevoort, R. T., & DIPAK Consortium (2025). Predicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology, 20(5), 608-618. https://doi.org/10.2215/cjn.0000000680

Vancouver

Bais T, Knol MGE, Xue L, Geertsema P, Vart P, Reichel F, et al. Predicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology. 2025;20(5):608-618. doi:10.2215/cjn.0000000680

BibTeX
@article{Bais2025,
  author = {Bais, Thomas and Knol, Martine G E and Xue, Laixi and Geertsema, Paul and Vart, Priya and Reichel, Franz and Arjune, Sita and Müller, Roman-Ulrich and Dekker, Shosha E I and Salih, Mahdi and Meijer, Esther and Gansevoort, Ron T and DIPAK Consortium, DIPAK Consortium},
  title = {Predicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2025},
  volume = {20},
  number = {5},
  pages = {608--618},
  doi = {10.2215/cjn.0000000680}
}
Kostenlos starten →